HUMAN GENOME SCIENCES, INC.
🏢 View company profile →711Patents
86Active
711Granted
46Portfolio score
Filing activity: Dec 22, 1993 → Aug 5, 2015 · 76 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7141547B2 | Albumin fusion proteins comprising GLP-1 polypeptides | Chemistry; Metallurgy | 197 | Expired |
| US7368531B2 | Human secreted proteins | Human Necessities | 195 | Expired |
| US6905688B2 | Albumin fusion proteins | Emerging Cross-Sectional Technologies | 155 | Expired |
| US7411051B2 | Antibodies to HDPPA04 polypeptide | Chemistry; Metallurgy | 128 | Expired |
| US7402312B2 | Antibodies to vascular endothelial growth factor 2 (VEGF-2) | Chemistry; Metallurgy | 106 | Expired |
| US7138501B2 | Antibodies that immunospecifically bind BLyS | Chemistry; Metallurgy | 102 | Expired |
| US6040157A | Vascular endothelial growth factor 2 | Chemistry; Metallurgy | 96 | Expired |
| US8329179B2 | Death domain containing receptor 4 antibodies and methods | Chemistry; Metallurgy | 94 | Active |
| US7592010B2 | Albumin fusion proteins | Chemistry; Metallurgy | 94 | Active |
| US5935820A | Polynucleotides encoding vascular endothelial growth factor 2 | Chemistry; Metallurgy | 93 | Expired |
| US5874240A | Human 4-1BB receptor splicing variant | Emerging Cross-Sectional Technologies | 91 | Expired |
| US7348003B2 | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors | Chemistry; Metallurgy | 90 | Expired |
| US6946134B1 | Albumin fusion proteins | Chemistry; Metallurgy | 90 | Expired |
| US7361341B2 | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors | Chemistry; Metallurgy | 89 | Expired |
| US7452538B2 | Death domain containing receptor 4 antibodies and methods | Emerging Cross-Sectional Technologies | 88 | Expired |
| US7476384B2 | Death domain containing receptor 4 antibody and methods | Chemistry; Metallurgy | 88 | Expired |
| US6573082B1 | Streptococcus pneumoniae antigens and vaccines | Human Necessities | 84 | Expired |
| US6541224B2 | Tumor necrosis factor delta polypeptides | Physics | 81 | Expired |
| US6420135B1 | Streptococcus pneumoniae polynucleotides and sequences | Human Necessities | 80 | Expired |
| US5932540A | Vascular endothelial growth factor 2 | Chemistry; Metallurgy | 77 | Expired |
| US6537966B1 | Follistatin-3 | Emerging Cross-Sectional Technologies | 76 | Expired |
| US5501969A | Human osteoclast-derived cathepsin | Human Necessities | 74 | Expired |
| US7189690B2 | Albumin fusion proteins | Chemistry; Metallurgy | 72 | Expired |
| US5780263A | Human CCN-like growth factor | Human Necessities | 72 | Expired |
| US6025154A | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 | Chemistry; Metallurgy | 70 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.